BPC-157 cost: what prescription therapy will cost.
BPC-157 prescription cost through compounding pharmacies is likely to be moderate compared to other peptide therapies, based on pre-restriction pricing. Here is a detailed cost breakdown based on pre-restriction compounding pharmacy pricing and current comparable peptide costs — covering injectable, oral, and BPC-157 + TB-500 stack pricing.
BPC-157 cost breakdown
| Component | Estimated cost | Notes |
|---|---|---|
| BPC-157 vial — 5 mg (injectable) | $35–$65 per vial | At 500 mcg/day, one 5 mg vial lasts ~10 days |
| BPC-157 vial — 10 mg (injectable) | $55–$95 per vial | Better per-mg value; lasts ~20 days at 500 mcg/day |
| BPC-157 capsules — 30ct (oral) | $50–$90 per bottle | 250 mcg per capsule; one month at 1 cap/day |
| Physician consultation (initial) | $100–$250 | Telehealth or in-person evaluation and prescription |
| Physician follow-up | $50–$100 | Typically every 4–6 weeks during active protocol |
| Supplies (injectable only) | $15–$25 per month | Insulin syringes, alcohol swabs, bacteriostatic water |
| Monthly total (injectable) | $120–$220 | After initial consultation, 500 mcg/day protocol |
| Monthly total (oral) | $80–$150 | No supply costs, simpler administration |
BPC-157 + TB-500 stack cost
The most common BPC-157 combination protocol is stacking with TB-500 (Thymosin Beta-4 fragment). TB-500 typically costs $50–$80 per 5 mg vial from compounding pharmacies. When both peptides are prescribed together, the combined BPC-157 cost rises to approximately $200–$350 per month for injectable protocols. Some compounding pharmacies offer pre-mixed BPC-157/TB-500 combination vials at a 10–15% discount versus purchasing separately.
Injectable vs oral cost comparison
Oral BPC-157 is approximately 30–40% cheaper per month than injectable when accounting for supply costs and reconstitution materials. For gut-focused applications where oral is the clinically preferred route, this creates both a clinical and financial advantage. For localized injury repair where injection near the site is preferred, the cost premium for injectable is justified by the targeted delivery mechanism.
Where to get BPC-157: compounding pharmacy access
If BPC-157 is reclassified to Category 1, the compound would be available through licensed 503A and 503B compounding pharmacies with a valid physician's prescription. This is not an over-the-counter supplement — it requires a prescription from a licensed medical provider, typically obtained through a telehealth peptide therapy consultation or an in-person visit with a physician specializing in regenerative medicine.
Research-grade BPC-157 currently available online without a prescription is not manufactured under pharmaceutical compounding standards, does not come with a certificate of analysis from a licensed pharmacy, and its purity and identity cannot be verified. The prescription pathway through compounding pharmacies exists specifically to ensure patients receive pharmaceutical-grade material prepared under USP 797 sterile compounding standards.
Insurance and payment options
Insurance coverage for compounded BPC-157 is extremely unlikely. Peptide therapy is considered elective, and BPC-157 lacks FDA approval — meaning no covered diagnosis code exists. BPC-157 prescription therapy will be cash-pay in virtually all cases. HSA and FSA eligibility depends on the plan administrator and whether the prescribing physician provides a letter of medical necessity. Some peptide therapy clinics offer subscription pricing or multi-month packages reducing the effective monthly BPC-157 cost by 15–25%.